Innovative determination of Let-7a for lung cancer diagnosis using a duplex specific nuclease (DSN)-based electrochemical biosensor.

In this study, we emphasize the importance of identifying Let-7a, a microRNA that is key in diagnosing and predicting lung cancer outcomes. Let-7a's function as a biomarker is essential, as it affects tumor suppression and controls cell differentiation and growth. We developed a novel device, an electrochemical biosensor based on Duplex Specific Nuclease (DSN), that is designed for the accurate detection of Let-7a. This biosensor has a very low detection limit of 3.9 aM, showing its high sensitivity. The design is easy to use, requiring little training to operate. Its small size and portability enable the possibility of bedside and home use, which is a significant improvement for personalized healthcare. This versatility of the biosensor is very promising, as it can be applied to other disease biomarkers besides lung cancer. We expect this technology to improve disease diagnosis and patient recovery tracking, playing an important role in the future of medical diagnostics. The use of such sensitive and specific biosensors can transform the way diseases are managed, providing timely and precise information on disease progression and treatment effectiveness. The potential for this technology to help advance personalized medicine and patient care is huge, creating new opportunities in medical diagnostics and therapy monitoring.